PureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapyUS biotech Vedanta Biosciences has been awarded up to $76.9 million to develop VE303 for high-risk Clostridioides difficile (C. Share XPureTech’s Vedanta Biosciences gets federal funding for C. Diff. microbiome therapyhttps://pharmaphorum.com/news/puretechs-vedanta-biosciences-gets-federal-funding-for-c-diff-microbiome-therapy/